On February 27, 2026, Incite Corp received a Complete Response Letter from the FDA for its supplemental application for Zynyz® to treat NSCLC, citing compliance issues at a third-party facility but acknowledging no efficacy concerns with the drug itself. The company plans to work with FDA and the facility to resolve the issue and potentially resubmit the application.